PapersPMID:42942425
Lactobacillus rhamnosus Lysate for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- RCT · 3 months
- Dose studied, every finding
- 100 mg twice daily for 12 weeks, then 3 months follow-up without treatment
- Population, every finding
- Adults aged 18-70 with MASLD (BMI 25-39.9, FLI >60); standard lifestyle-modification programme and counselling in both arms; between-group time-by-treatment interaction over 6 months
No finding here moved its endpoint.
What did not
How to read these marks →“ALT and AST decreased within the Del-Immune V® Extra group at month 3 (ALT: −5.88 U/L, 95% CI: −10.27 to −1.49; p = 0.011; AST: −2.78 U/L, 95% CI: −4.74 to −0.81; p = 0.007), but the between-group interaction tests were not significant (ALT p = 0.340; AST p = 0.111).”
- Interests
- Industry funded
- Interests
- Industry funded
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Adults aged 18-70 with MASLD (fatty liver index above 60, BMI 25-39.9 kg/m2) at the Kyiv City Clinical Endocrinology Centre, Ukraine
- Participants
- 52
- Comparator
- placebo
- Duration
- 84 days
- Endpoints measured
- 35